Halozyme Therapeutics | HALO - Operating Profit


Halozyme Therapeutics reported $-63.72M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 4.61B 777M Jun/2026
Baxter International USD 276M 210M Jun/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
DBV Technologies USD -47.9M 2.85M Mar/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
MannKind USD -68.23M 8.76M Jun/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Pfizer USD 667M 4.32B Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
United Therapeutics USD 330.8M 5M Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024